03-03-2025
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:
Leerink's Global Healthcare Conference 2025, Miami
Fireside Chat
Tuesday, March 11, 2025, at 4:20 pm ET
A live webcast and replay, when available, will be available under 'Events and Presentations' in the News & Investors section of the Tourmaline Bio website at
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on LinkedIn or X.
Media Contact
Scient PR
Sarah Mishek
Investor Contact
Meru Advisors
Lee M. Stern
